N2OFF Reports Preliminary Data from MitoCareX Bio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 22 2026
0mins
N2OFF announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro--inflammatory responses in human immune cells using its proprietary discovery platform. Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on NITO
About NITO
N2OFF Inc. is a clean tech company, which is engaged in providing sustainable solutions for agri- tech. The Company is focused on sustainable operations in various industries, such as agri-food tech, potent greenhouse gas emissions and solar projects, specialized in eco-crop protection that helps reduce food waste and ensure food safety while reducing the use of pesticides. Its solutions are based on a blend of food acids combined with certain types of oxidizing agent-based sanitizers and, in some cases, with fungicides at low concentrations. Its products have a synergistic effect when combined with these oxidizing agent-based sanitizers and fungicides. Its green solutions are capable of cleaning, sanitizing and controlling pathogens in fresh produce. The Company’s products include Processing Aids-SavePROTECT or PeroStar, which are an application added to fruit and vegetable wash water as a processing aid to peracetic acid to increase its efficiency against plant pathogens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
N2OFF Highlights New Study on SLC25A Biomarkers and Therapeutic Targets
- Research Publication: N2OFF's wholly-owned subsidiary MitoCareX Bio co-authored a study with the University of Bari and the University of Pittsburgh, highlighting SLC25A mitochondrial carriers as potential biomarkers for spaceflight-induced dysfunction, emphasizing their significance in tumor metabolic adaptation and therapy resistance.
- Data Integration Analysis: The study integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes under microgravity and spaceflight-related stressors, revealing differential regulation of multiple carriers that supports their potential as biomarkers of mitochondrial and metabolic dysfunction.
- Structural Case Study: The research specifically investigates the ADP/ATP carrier AAC3, using comparative modeling and structure-function analyses to illustrate how targeting carrier conformational features can rescue mitochondrial bioenergetics under stress, further advancing precision oncology research.
- Investment Strategy Alignment: N2OFF is not only focused on drug discovery but also invests in European renewable energy assets using the RTB business model, currently serving as the lead investor in four solar projects across three EU countries, demonstrating its strategic positioning in sustainable development.
Continue Reading
N2OFF Partners with Solterra to Advance German Solar Project
- Significant Project Progress: N2OFF's partnership with Solterra has achieved key milestones in reducing permitting risks for its German solar project, which is on track for approval in Q3 2026, indicating strong positioning in the European market.
- Financial Optimization: By advancing $340,000, Solterra secured more favorable profit-sharing terms, expected to create approximately $1.7 million in project value, enhancing the company's financial flexibility and profitability.
- Strategic Investment: This transaction represents a highly efficient redeployment of limited near-term capital, not only improving long-term project economics but also enhancing future exit or operating return potential, showcasing N2OFF's discipline in capital allocation.
- Optimistic Market Outlook: With systematic reductions in regulatory risks and tightening development economics, N2OFF's advancement along the RTB value curve will lay a solid foundation for the company's long-term growth in the renewable energy sector.
Continue Reading